# Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients

> **NCT03459287** · PHASE3 · COMPLETED · sponsor: **Cerus Corporation** · enrollment: 581 (actual)

## Conditions studied

- Anemia

## Interventions

- **DEVICE:** INTERCEPT
- **DEVICE:** Control

## Key facts

- **NCT ID:** NCT03459287
- **Lead sponsor:** Cerus Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-05
- **Primary completion:** 2023-12-04
- **Final completion:** 2024-03-05
- **Target enrollment:** 581 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03459287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03459287, "Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03459287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*